Is there a role for curcumin in the treatment of bipolar disorder?

Medical Hypotheses

Volumn 80, Issue 5, 2013, Pages 606-612

  Brietzke, Elisa ^a   Mansur, Rodrigo B ^a   Zugman, Andre ^a   Carvalho, André F ^b   Macêdo, Danielle S ^b   Cha, Danielle S ^c   Abílio, Vanessa C ^a   McIntyre, Roger S ^c  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b FEDERAL UNIVERSITY OF CEARÁ   (Brazil)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; CARBAMAZEPINE; CELECOXIB; CURCUMIN; CYCLOOXYGENASE 2; FLUOXETINE; IMIPRAMINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LITHIUM; PLACEBO; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR ALPHA; VALPROIC ACID;

ANTIDEPRESSANT ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; BIPOLAR DISORDER; CELL ACTIVATION; CELL PROTECTION; CELL SURVIVAL; DEPRESSION; DRUG MECHANISM; DRUG TARGETING; GENE EXPRESSION REGULATION; GENETIC POLYMORPHISM; HUMAN; INFLAMMATION; MICROGLIA; NONHUMAN; OXIDATIVE STRESS; PROTEIN FUNCTION; PROTEIN INDUCTION; PSYCHOPHARMACOTHERAPY; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BIPOLAR DISORDER; BRAIN; CURCUMIN; CYTOKINES; HUMANS; IMMUNOLOGIC FACTORS; MODELS, BIOLOGICAL; TRANSCRIPTION FACTORS;

CURCUMA LONGA;

EID: 84875626218     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2013.02.001     Document Type: Article

References (124)

1. WHO Prevention of mental disorders effective interventions and policy options 2004, World Health Organization, Geneva, Switzerland.
2. Andreazza A.C., Cassini C., Rosa A.R., et al. Serum S100B and antioxidant enzymes in bipolar patients. J Psychiatr Res 2007, 41:523-529.
3. Angst J., Gamma A., Lewinsohn P. The evolving epidemiology of bipolar disorder. World Psychiatry 2002, 1:146-148.
4. Ketter T.A. Diagnostic features, prevalence, and impact of bipolar disorder. J Clin Psychiatry 2010, 71:e14.
5. Cassidy F., Ahearn E., Carroll B.J. Elevated frequency of diabetes mellitus in hospitalized manic-depressive patients. Am J Psychiatry 1999, 156:1417-1420.
6. Martinez-Aran A., Vieta E., Colom F., et al. Cognitive impairment in euthymic bipolar patients: implications for clinical and functional outcome. Bipolar Disord 2004, 6:224-232.
7. Fagiolini A., Frank E., Scott J.A., Turkin S., Kupfer D.J. Metabolic syndrome in bipolar disorder: findings from the bipolar disorder center for pennsylvanians. Bipolar Disord 2005, 7:424-430.
8. McIntyre R.S., Danilewitz M., Liauw S.S., et al. Bipolar disorder and metabolic syndrome: an international perspective. J Affect Disord 2010, 126:366-387.
9. Newcomer J.W. Medical risk in patients with bipolar disorder and schizophrenia. J Clin Psychiatry 2006, 67(Suppl. 9):25-30. discussion 36-42.
10. Fagiolini A., Chengappa K.N., Soreca I., Chang J. Bipolar disorder and the metabolic syndrome: causal factors, psychiatric outcomes and economic burden. CNS Drugs 2008, 22:655-669.
11. Yatham L.N., Kennedy S.H., Schaffer A., et al. Canadian network for mood and anxiety treatments (CANMAT) and international society for bipolar disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update. Bipolar Disord 2009, 11(2009):225-255.
12. Fountoulakis K.N. Refractoriness in bipolar disorder: definitions and evidence-based treatment. CNS Neurosci Ther 2012, 18:227-237.
13. McIntyre R.S., Alsuwaidan M., Goldstein B.I., et al. The canadian network for mood and anxiety treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid metabolic disorders. Ann Clin Psychiatry 2012, 24:69-81.
14. Berk M., Kapczinski F., Andreazza A.C., et al. Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neurosci Biobehav Rev 2011, 35:804-817.
15. Kapczinski F., Vieta E., Andreazza A.C., et al. Allostatic load in bipolar disorder: implications for pathophysiology and treatment. Neurosci Biobehav Rev 2008, 32:675-692.
16. Sarris J., Lake J., Hoenders R. Bipolar disorder and complementary medicine: current evidence, safety issues, and clinical considerations. J Altern Complement Med 2011, 17:881-890.
17. Perry E., Howes M.J. Medicinal plants and dementia therapy: herbal hopes for brain aging?. CNS Neurosci Ther 2011, 17:683-698.
18. Manber R., Allen J.J., Morris M.E. Alternative treatments for depression: empirical support and relevance to women. J Clin Psychiatry 2002, 63:628-640.
19. Sarris J., Mischoulon D., Schweitzer I. Adjunctive nutraceuticals with standard pharmacotherapies in bipolar disorder: a systematic review of clinical trials. Bipolar Disord 2011, 13:454-465.
20. Aggarwal B.B., Sung B. Pharmacological basis for the role of curcumin in chronic diseases: an age-old spice with modern targets. Trends Pharmacol Sci 2009, 30:85-94.
21. Olivera A., Moore T.W., Hu F., et al. Inhibition of the NF-κB signaling pathway by the curcumin analog, 3,5-bis(2-pyridinylmethylidene)-4-piperidone (EF31): anti-inflammatory and anti-cancer properties. Int Immunopharmacol 2012, 12:368-377.
22. Ray B., Lahiri D.K. Neuroinflammation in Alzheimer's disease: different molecular targets and potential therapeutic agents including curcumin. Curr Opin Pharmacol 2009, 9:434-444.
23. Pari L., Tewas D., Eckel J. Role of curcumin in health and disease. Arch Physiol Biochem 2008, 114:127-149.
24. Ray B., Lahiri D. Neuroinflammation in Alzheimer's disease: different molecular targets and potential therapeutic agents including curcumin. Curr Opin Pharmacol 2009, 9:434-444.
25. Sookram C., Tan M., Daya R., Heffernan S., Mishra R.K. Curcumin prevents haloperidol-induced development of abnormal oro-facial movements: possible implications of Bcl-XL in its mechanism of action. Synapse 2011, 65:788-794.
26. Aggarwal B.B., Harikumar K.B. Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. Int J Biochem Cell Biol 2009, 41:40-59.
27. Maheshwari R.K., Singh A.K., Gaddipati J., Srimal R.C. Multiple biological activities of curcumin: a short review. Life Sci 2006, 78:2081-2087.
28. Goel A., Kunnumakkara A.B., Aggarwal B.B. Curcumin as " Curecumin" : from kitchen to clinic. Biochem Pharmacol 2008, 75:787-809.
29. Spiliotaki M., Salpeas V., Malitas P., Alevizos V., Moutsatsou P. Altered glucocorticoid receptor signaling cascade in lymphocytes of bipolar disorder patients. Psychoneuroendocrinology 2006, 31:748-760.
30. Politi P., Brondino N., Emanuele E. Increased proapoptotic serum activity in patients with chronic mood disorders. Arch Med Res 2008, 39:242-245.
31. Kim H.W., Rapoport S.I., Rao J.S. Altered expression of apoptotic factors and synaptic markers in postmortem brain from bipolar disorder patients. Neurobiol Dis 2010, 37:596-603.
32. Rao J.S., Bazinet R.P., Rapoport S.I., Lee H.J. Chronic treatment of rats with sodium valproate downregulates frontal cortex NF-κB DNA binding activity and COX-2 mRNA. Bipolar Disord 2007, 9:513-520.
33. Quiroz J.A., Machado-Vieira R., Zarate C.A., Manji H.K. Novel insights into lithium's mechanism of action: neurotrophic and neuroprotective effects. Neuropsychobiology 2010, 62:50-60.
34. Berk M., Conus P., Kapczinski F., et al. From neuroprogression to neuroprotection: implications for clinical care. Med J Aust 2010, 193:S36-S40.
35. Kapczinski F., Dal-Pizzol F., Teixeira A.L., et al. Peripheral biomarkers and illness activity in bipolar disorder. J Psychiatr Res 2011, 45:156-161.
36. Cowansage K.K., LeDoux J.E., Monfils M.H. Brain-derived neurotrophic factor: a dynamic gatekeeper of neural plasticity. Curr Mol Pharmacol 2010, 3:12-29.
37. Fernandes B.S., Gama C.S., Cereser K.M., et al. Brain-derived neurotrophic factor as a state-marker of mood episodes in bipolar disorders: a systematic review and meta-regression analysis. J Psychiatr Res 2011, 45:995-1004.
38. Tramontina J.F., Andreazza A.C., Kauer-Sant'anna M., et al. Brain-derived neurotrophic factor serum levels before and after treatment for acute mania. Neurosci Lett 2009, 452:111-113.
39. Hashimoto K. Brain-derived neurotrophic factor as a biomarker for mood disorders: an historical overview and future directions. Psychiatry Clin Neurosci 2010, 64:341-357.
40. Hu Y., Yu X., Yang F., et al. The level of serum brain-derived neurotrophic factor is associated with the therapeutic efficacy of modified electroconvulsive therapy in Chinese patients with depression. J ECT 2010, 26:121-125.
41. Yoshimura R., Ikenouchi-Sugita A., Hori H., et al. Adding a low dose atypical antipsychotic drug to an antidepressant induced a rapid increase of plasma brain-derived neurotrophic factor levels in patients with treatment-resistant depression. Prog Neuropsychopharmacol Biol Psychiatry 2010, 34:308-312.
42. de Sousa R.T., van de Bilt M.T., Diniz B.S., et al. Lithium increases plasma brain-derived neurotrophic factor in acute bipolar mania: a preliminary 4weeks study. Neurosci Lett 2011, 494:54-56.
43. Neves-Pereira M., Mundo E., Muglia P., King N., Macciardi F., Kennedy J.L. The brain-derived neurotrophic factor gene confers susceptibility to bipolar disorder: evidence from a family-based association study. Am J Hum Genet 2002, 71:651-655.
44. Sklar P., Gabriel S.B., McInnis M.G., et al. Family-based association study of 76 candidate genes in bipolar disorder: BDNF is a potential risk locus. Mol Psychiatry 2002, 7:579-593.
45. Liu L., Foroud T., Xuei X., et al. Evidence of association between brain-derived neurotrophic factor gene and bipolar disorder. Psychiatr Genet 2008, 18:267-274.
46. Xu F., Plummer M.R., Len G.W., et al. Brain-derived neurotrophic factor rapidly increases NMDA receptor channel activity through Fyn-mediated phosphorylation. Brain Res 2006, 1121:22-34.
47. Wei S., Xu H., Xia D., Zhao R. Curcumin attenuates the effects of transport stress on serum cortisol concentration, hippocampal NO production, and BDNF expression in the pig. Domest Anim Endocrinol 2010, 39:231-239.
48. Karatsoreos I.N., McEwen B.S. Psychobiological allostasis: resistance, resilience and vulnerability. Trends Cogn Sci 2011, 15:576-584.
49. Xu Y., Ku B., Cui L., et al. Curcumin reverses impaired hippocampal neurogenesis and increases serotonin receptor 1A mRNA and brain-derived neurotrophic factor expression in chronically stressed rats. Brain Res 2007, 1162:9-18.
50. Wang R., Li Y.H., Xu Y., et al. Curcumin produces neuroprotective effects via activating brain-derived neurotrophic factor/TrkB-dependent MAPK and PI-3K cascades in rodent cortical neurons. Prog Neuropsychopharmacol Biol Psychiatry 2010, 34:147-153.
51. Wang R., Li Y.B., Li Y.H., Xu Y., Wu H.L., Li X.J. Curcumin protects against glutamate excitotoxicity in rat cerebral cortical neurons by increasing brain-derived neurotrophic factor level and activating TrkB. Brain Res 2008, 1210:84-91.
52. Lennon S.V., Martin S.J., Cotter T.G. Dose-dependent induction of apoptosis in human tumour cell lines by widely diverging stimuli. Cell Prolif 1991, 24:203-214.
53. Sun X., Wang J.F., Tseng M., Young L.T. Downregulation in components of the mitochondrial electron transport chain in the postmortem frontal cortex of subjects with bipolar disorder. J Psychiatry Neurosci 2006, 31:189-196.
54. Andreazza A.C., Kauer-Sant'anna M., Frey B.N., et al. Oxidative stress markers in bipolar disorder: a meta-analysis. J Affect Disord 2008, 111:135-144.
55. Machado-Vieira R., Andreazza A.C., Viale C.I., et al. Oxidative stress parameters in unmedicated and treated bipolar subjects during initial manic episode: a possible role for lithium antioxidant effects. Neurosci Lett 2007, 421:33-36.
56. Benes F.M., Matzilevich D., Burke R.E., Walsh J. The expression of proapoptosis genes is increased in bipolar disorder, but not in schizophrenia. Mol Psychiatry 2006, 11:241-251.
57. Konradi C., Eaton M., MacDonald M.L., Walsh J., Benes F.M., Heckers S. Molecular evidence for mitochondrial dysfunction in bipolar disorder. Arch Gen Psychiatry 2004, 61:300-308.
58. Ak T., Gulcin I. Antioxidant and radical scavenging properties of curcumin. Chem Biol Interact 2008, 174:27-37.
59. Feng J.Y., Liu Z.Q. Phenolic and enolic hydroxyl groups in curcumin: which plays the major role in scavenging radicals?. J Agric Food Chem 2009, 57:11041-11046.
60. Masuda T., Hidaka K., Shinohara A., Maekawa T., Takeda Y., Yamaguchi H. Chemical studies on antioxidant mechanism of curcuminoid: analysis of radical reaction products from curcumin. J Agric Food Chem 1999, 47:71-77.
61. Kandhare A.D., Raygude K.S., Ghosh P., Ghule A.E., Bodhankar S.L. Therapeutic role of curcumin in prevention of biochemical and behavioral aberration induced by alcoholic neuropathy in laboratory animals. Neurosci Lett 2012, 511:18-22.
62. Lee N.H., Lee Y.H., Bhattari G., et al. Reactive oxygen species removal activity of davallialactone reduces lipopolysaccharide-induced pulpal inflammation through inhibition of the extracellular signal-regulated kinase 1/2 and nuclear factor kappa b pathway. J Endod 2011, 37:491-495.
63. Trakhtenberg E.F., Goldberg J.L. Immunology. Neuroimmune communication. Science 2011, 334:47-48.
64. Yirmiya R., Goshen I. Immune modulation of learning, memory, neural plasticity and neurogenesis. Brain Behav Immun 2011, 25:181-213.
65. Dean B. Understanding the role of inflammatory-related pathways in the pathophysiology and treatment of psychiatric disorders: evidence from human peripheral studies and CNS studies. Int J Neuropsychopharmacol 2011, 14:997-1012.
66. Goldstein B.I., Kemp D.E., Soczynska J.K., McIntyre R.S. Inflammation and the phenomenology, pathophysiology, comorbidity, and treatment of bipolar disorder: a systematic review of the literature. J Clin Psychiatry 2009, 70:1078-1090.
67. Breunis M.N., Kupka R.W., Nolen W.A., et al. High numbers of circulating activated T cells and raised levels of serum IL-2 receptor in bipolar disorder. Biol Psychiatry 2003, 53:157-165.
68. Boufidou F., Nikolaou C., Alevizos B., Liappas I.A., Christodoulou G.N. Cytokine production in bipolar affective disorder patients under lithium treatment. J Affect Disord 2004, 82:309-313.
69. Kauer-Sant'Anna M., Kapczinski F., Andreazza A.C., et al. Brain-derived neurotrophic factor and inflammatory markers in patients with early- vs. late-stage bipolar disorder. Int J Neuropsychopharmacol 2009, 12:447-458.
70. Harris R.E. Cyclooxygenase-2 (cox-2) blockade in the chemoprevention of cancers of the colon, breast, prostate, and lung. Inflammopharmacology 2009, 17:55-67.
71. Belcaro G., Cesarone M.R., Dugall M., et al. Efficacy and safety of Meriva(R), a curcumin-phosphatidylcholine complex, during extended administration in osteoarthritis patients. Altern Med Rev 2010, 15:337-344.
72. Lee K.H., Abas F., Alitheen N.B., Shaari K., Lajis N.H., Ahmad S. A curcumin derivative, 2,6-bis(2,5-dimethoxybenzylidene)-cyclohexanone (BDMC33) attenuates prostaglandin E2 synthesis via selective suppression of cyclooxygenase-2 in IFN-gamma/LPS-stimulated macrophages. Molecules 2011, 16:9728-9738.
73. Kim H.W., Rapoport S.I., Rao J.S. Altered arachidonic acid cascade enzymes in postmortem brain from bipolar disorder patients. Mol Psychiatry 2011, 16:419-428.
74. Chang M.C., Contreras M.A., Rosenberger T.A., Rintala J.J., Bell J.M., Rapoport S.I. Chronic valproate treatment decreases the in vivo turnover of arachidonic acid in brain phospholipids: a possible common effect of mood stabilizers. J Neurochem 2001, 77:796-803.
75. Nery F.G., Monkul E.S., Hatch J.P., et al. Celecoxib as an adjunct in the treatment of depressive or mixed episodes of bipolar disorder: a double-blind, randomized, placebo-controlled study. Hum Psychopharmacol 2008, 23:87-94.
76. Karlstetter M., Lippe E., Walczak Y., et al. Curcumin is a potent modulator of microglial gene expression and migration. J Neuroinflammation 2011, 8:125.
77. Lim G.P., Chu T., Yang F., Beech W., Frautschy S.A., Cole G.M. The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J Neurosci 2001, 21:8370-8377.
78. Brietzke E., Kapczinski F. TNF-α as a molecular target in bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32:1355-1361.
79. Shanmugam M.K., Kannaiyan R., Sethi G. Targeting cell signaling and apoptotic pathways by dietary agents: role in the prevention and treatment of cancer. Nutr Cancer 2011, 63:161-173.
80. Brietzke E., Kauer-Sant'Anna M., Teixeira A.L., Kapczinski F. Abnormalities in serum chemokine levels in euthymic patients with bipolar disorder. Brain Behav Immun 2009, 23:1079-1082.
81. Dodd S., Maes M., Anderson G., Dean O.M., Moylan S., Berk M. Putative neuroprotective agents in neuropsychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry 2013, 42:135-145.
82. Clay H.B., Sillivan S., Konradi C. Mitochondrial dysfunction and pathology in bipolar disorder and schizophrenia. Int J Dev Neurosci 2011, 29:311-324.
83. Politi P., Brondino N., Emanuele E. Increased proapoptotic serum activity in patients with chronic mood disorders. Arch Med Res 2008, 39:242-245.
84. Lyoo I.K., Sung Y.H., Dager S.R., et al. Regional cerebral cortical thinning in bipolar disorder. Bipolar Disord 2006, 8:65-74.
85. Kim H.-W., Rapoport S.I., Rao J.S. Altered expression of apoptotic factors and synaptic markers in postmortem brain from bipolar disorder patients. Neurobiol Dis 2010, 37:596-603.
86. Chuang D.M. Neuroprotective and neurotrophic actions of the mood stabilizer lithium: can it be used to treat neurodegenerative diseases?. Crit Rev Neurobiol 2004, 16:83-90.
87. Chuang D.M. The antiapoptotic actions of mood stabilizers: molecular mechanisms and therapeutic potentials. Ann N Y Acad Sci 2005, 1053:195-204.
88. Mora A., Gonzalez-Polo R.A., Fuentes J.M., Soler G., Centeno F. Different mechanisms of protection against apoptosis by valproate and Li+. Eur J Biochem 1999, 266:886-891.
89. Ramachandran C., Rodriguez S., Ramachandran R., et al. Expression profiles of apoptotic genes induced by curcumin in human breast cancer and mammary epithelial cell lines. Anticancer Res 2005, 25:3293-3302.
90. Pan J., Li H., Ma J.F., et al. Curcumin inhibition of JNKs prevents dopaminergic neuronal loss in a mouse model of Parkinson's disease through suppressing mitochondria dysfunction. Transl Neurodegener 2012, 1:16.
91. Dai M.-C., Zhong Z.-H., Sun Y.-H., et al. Curcumin protects against iron induced neurotoxicity in primary cortical neurons by attenuating necroptosis. Neurosci Lett 2013, 536:41-46.
92. Zhou H., Beevers C.S., Huang S. The targets of curcumin. Curr Drug Targets 2011, 12:332-347.
93. Kulkarni S., Dhir A., Akula K.K. Potentials of curcumin as an antidepressant. Sci World J 2009, 9:1233-1241.
94. Kulkarni S.K., Akula K.K., Deshpande J. Evaluation of antidepressant-like activity of novel water-soluble curcumin formulations and St. John's wort in behavioral paradigms of despair. Pharmacology 2012, 89:83-90.
95. Kulkarni S.K., Bhutani M.K., Bishnoi M. Antidepressant activity of curcumin: involvement of serotonin and dopamine system. Psychopharmacology (Berl) 2008, 201:435-442.
96. Mei X., Xu D., Xu S., Zheng Y. Gastroprotective and antidepressant effects of a new zinc(II)-curcumin complex in rodent models of gastric ulcer and depression induced by stresses. Pharmacol Biochem Behav 2011, 99:66-74.
97. Sanmukhani J., Anovadiya A., Tripathi C.B. Evaluation of antidepressant like activity of curcumin and its combination with fluoxetine and imipramine: an acute and chronic study. Acta Pol Pharm 2011, 68:769-775.
98. Wang R., Xu Y., Wu H.L., et al. The antidepressant effects of curcumin in the forced swimming test involve 5-HT1 and 5-HT2 receptors. Eur J Pharmacol 2008, 578:43-50.
99. Xu Y., Ku B.S., Yao H.Y., et al. The effects of curcumin on depressive-like behaviors in mice. Eur J Pharmacol 2005, 518:40-46.
100. Xu Y., Ku B.S., Yao H.Y., et al. Antidepressant effects of curcumin in the forced swim test and olfactory bulbectomy models of depression in rats. Pharmacol Biochem Behav 2005, 82:200-206.
101. Bhutani M.K., Bishnoi M., Kulkarni S.K. Anti-depressant like effect of curcumin and its combination with piperine in unpredictable chronic stress-induced behavioral, biochemical and neurochemical changes. Pharmacol Biochem Behav 2009, 92:39-43.
102. Li Y.C., Wang F.M., Pan Y., et al. Antidepressant-like effects of curcumin on serotonergic receptor-coupled AC-cAMP pathway in chronic unpredictable mild stress of rats. Prog Neuropsychopharmacol Biol Psychiatry 2009, 33:435-449.
103. Huang Z., Zhong X.M., Li Z.Y., Feng C.R., Pan A.J., Mao Q.Q. Curcumin reverses corticosterone-induced depressive-like behavior and decrease in brain BDNF levels in rats. Neurosci Lett 2011, 493:145-148.
104. Arora V., Kuhad A., Tiwari V., Chopra K. Curcumin ameliorates reserpine-induced pain-depression dyad: behavioural, biochemical, neurochemical and molecular evidences. Psychoneuroendocrinology 2011, 36:1570-1581.
105. White B., Judkins D.Z. Clinical inquiry. Does turmeric relieve inflammatory conditions?. J Fam Pract 2011, 60:155-156.
106. Deodhar S.D., Sethi R., Srimal R.C. Preliminary study on antirheumatic activity of curcumin (diferuloyl methane). Indian J Med Res 1980, 71:632-634.
107. Heng M.C., Song M.K., Harker J., Heng M.K. Drug-induced suppression of phosphorylase kinase activity correlates with resolution of psoriasis as assessed by clinical, histological and immunohistochemical parameters. Br J Dermatol 2000, 143:937-949.
108. Holt P.R., Katz S., Kirshoff R. Curcumin therapy in inflammatory bowel disease: a pilot study. Dig Dis Sci 2005, 50:2191-2193.
109. Hanai H., Iida T., Takeuchi K., et al. Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol 2006, 4:1502-1506.
110. Shoskes D., Lapierre C., Cruz-Correa M., et al. Beneficial effects of the bioflavonoids curcumin and quercetin on early function in cadaveric renal transplantation: a randomized placebo controlled trial. Transplantation 2005, 80:1556-1559.
111. Chandra V., Pandav R., Dodge H.H., et al. Incidence of Alzheimer's disease in a rural community in India: the Indo-US study. Neurology 2001, 57:985-989.
112. Tang H., Lu D., Pan R., Qin X., Xiong H., Dong J. Curcumin improves spatial memory impairment induced by human immunodeficiency virus type 1 glycoprotein 120 V3 loop peptide in rats. Life Sci 2009, 85:1-10.
113. Ringman J.M., Frautschy S.A., Cole G.M., Masterman D.L., Cummings J.L. A potential role of the curry spice curcumin in Alzheimer's disease. Curr Alzheimer Res 2005, 2:131-136.
114. Baum L., Lam C.W., Cheung S.K., et al. Six-month randomized, placebo-controlled, double-blind, pilot clinical trial of curcumin in patients with Alzheimer disease. J Clin Psychopharmacol 2008, 28:110-113.
115. Sharma R.A., Steward W.P., Gescher A.J. Pharmacokinetics and pharmacodynamics of curcumin. Adv Exp Med Biol 2007, 595:453-470.
116. Pan M.H., Huang T.M., Lin J.K. Biotransformation of curcumin through reduction and glucuronidation in mice. Drug Metab Dispos 1999, 27:486-494.
117. Perkins S., Verschoyle R.D., Hill K., et al. Chemopreventive efficacy and pharmacokinetics of curcumin in the min/plus mouse, a model of familial adenomatous polyposis. Cancer Epidemiol Biomarkers Prev 2002, 11:535-540.
118. Anand P., Kunnumakkara A.B., Newman R.A., Aggarwal B.B. Bioavailability of curcumin: problems and promises. Mol Pharm 2007, 4:807-818.
119. Cheng A.L., Hsu C.H., Lin J.K., et al. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res 2001, 21:2895-2900.
120. Rasyid A., Lelo A. The effect of curcumin and placebo on human gall-bladder function: an ultrasound study. Aliment Pharmacol Ther 1999, 13:245-249.
121. Rasyid A., Rahman A.R., Jaalam K., Lelo A. Effect of different curcumin dosages on human gall bladder. Asia Pac J Clin Nutr 2002, 11:314-318.
122. Srivastava K.C., Bordia A., Verma S.K. Curcumin, a major component of food spice turmeric (Curcuma longa) inhibits aggregation and alters eicosanoid metabolism in human blood platelets. Prostaglandins Leukot Essent Fatty Acids 1995, 52:223-227.
123. Taylor R.A., Leonard M.C. Curcumin for inflammatory bowel disease: a review of human studies. Altern Med Rev 2011, 16:152-156.
124. Andreescu C., Mulsant B.H., Emanuel J.E. Complementary and alternative medicine in the treatment of bipolar disorder-a review of the evidence. J Affect Disord 2008, 110:16-26.